Search

  • Contact Us
  • Quick Order

Meet Thermo Fisher Scientific at College of American Pathologists (CAP) Annual Meeting 2026

October 3-5, 2026

Las Vegas, NV, USA

Discover the power of rapid NGS

Stop by the Thermo Fisher Scientific booth 320 for a hands-on look at the Ion Torrent Genexus Dx system and the precision oncology solutions built to run on it—from rapid, in-house genomic profiling solutions including our FDA-approved IVD test, Oncomine Dx Express Test. Our specialists will be on hand to walk through and answer questions on bringing NGS testing in-house.

Visit our booth to learn about:
  • Oncomine Dx Express Test—See our flagship FDA-approved NGS companion diagnostic in action, delivering biomarker results from tissue to report in as little as 24 hours.
  • Ion Torrent Genexus Dx System—Explore the automated, sample-to-report platform powering Oncomine Dx Express Test, purpose-built to bring rapid NGS testing to labs of any experience level.
  • Sample reports—Get a firsthand look at reports, and talk through what in-house NGS could look like for your lab.
  • Rapid genomic profiling solutions—Discover all our assays designed for labs looking to expand biomarker coverage and drive deeper genomic insights.

Hear from experts at our industry workshop

Title: From Verification to Results: Simplifying Oncology NGS with an Integrated IVD Workflow

Date: October 4, 2026

Time: 11:45 am – 12:45 pm PT

Room: Meursault 2 (Wynn Resort, Las Vegas)

 

During this workshop you’ll learn about:

  • Our integrated IVD NGS workflow, combining demonstrated performance with rapid turnaround and workflow automation for clinical oncology testing.
  • A single, integrated software solution that simplifies oncology NGS analysis by automating analysis, QC, and results generation while guiding users from run setup to report sign-out—without requiring bioinformatics expertise.
  • How IVD test verification differs from LDT validation and how an IVD approach can simplify oncology NGS implementation.

Add this event to your calendar below.

Logos are trademarks of Google and Microsoft.

Speakers

Kevin Rivera, PhD

Sr. Medical Scientific Liasion
Thermo Fisher Scientific

Theresa Wheeler

Product Manager

Thermo Fisher Scientific

Xia Li, PhD, FACMG, DABMGG, MB/CG (ASCP)

Medical Director
Clin-Path Diagnostics

Watch our CAP 2025 workshop

Last year's "Introduction of New IVD Solution for Rapid NGS Profiling in Oncology" workshop drew nearly 100 registrants and stood out as one of the best-attended sessions at CAP 2025, featuring firsthand perspectives from anatomic pathologists and early Oncomine Dx Express Test adopters on what rapid, in-house genomic profiling means for the future of precision oncology.

Featured solutions

Oncomine Dx Express Test US

The newly FDA-approved Oncomine Dx Express Test is designed to simplify the NGS workflow and connect patients everywhere to precision oncology. Capable of being implemented in even labs without NGS expertise close to patients, it delivers results within just 24 hours, from tissue sample to report. 

Genexus Dx System

The Ion Torrent Genexus Dx System is a clinical NGS platform for in vitro diagnostic (IVD) testing that delivers biomarker results in as little as 24 hours. This two-instrument system automates the main steps in the NGS workflow, including nucleic acid purification and quantification, library preparation, sequencing, bioinformatics analysis, and reporting.

The Genexus Dx Purification System and Genexus Dx Integrated Sequencer work together with Genexus Dx Software, tracking sample information and results automatically through the process.

Services and support

Quality and efficiency in delivering patient test results shouldn’t be compromised under any circumstances. We can support your mission with our innovative services and expertise. We’re here to help ensure the quality and efficiency of your work in delivering patient test results with confidence in your instruments and systems.

Literature

Oncomine Dx Express Test brochure

Oncomine Dx Express Test physician flyer

Genexus Dx System brochure

The Oncomine DX Express Test is indicated as a companion diagnostic (CDx) to identify non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations for treatment with ZEGFROVY™ (sunvozertinib) in accordance with the approved therapeutic product labeling. The Oncomine Dx Express Test detects biomarkers recommended by professional guidelines for multiple solid tumors, including substitutions, insertions, and deletions in 42 genes, copy number variants in 10 genes, and fusions or splice variants in 18 genes.

For In Vitro Diagnostic Use.

PMR-008827